Jiangyan Zhang

Jiangyan Zhang

Auto-generated profile, based on publicly available information

Jiangyan Zhang

Center for Immunity and Inflammation, Rutgers University New Jersey Medical School 4 , Newark, NJ

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 October 2024 in Journal of Experimental Medicine
Verified
Journal Article
Open access
DDDaiyong Deng
Daiyong Deng
HBHabeebunnisa Begum
Habeebunnisa Begum
TLTong Liu
Tong Liu
JZJiangyan Zhang
Jiangyan Zhang
QZQiang Zhang
Qiang Zhang
PHPingping Hou
Pingping Hou
Resistance to KRAS therapy in pancreatic ductal adenocarcinoma (PDAC) involves cellular plasticity, particularly the epithelial-to-mesenchymal transition (EMT), which poses challenges for effective targeting. Chronic pancreatitis, a known risk factor for PDAC, elevates TGFβ levels in the tumor microenvironment (TME), promoting resistance to KRAS therapy. Mechanistically, TGFβ induces the formation of a novel protein complex composed of SMAD3, SMAD4, and the nuclear factor NFAT5, triggering EMT and resistance by activating key mediators such as S100A4. Inhibiting NFAT5 attenuates pancreatitis-induced resistance to KRAS inhibition and extends mouse survival. Additionally, TGFβ stimulates PDAC cells to secrete CCL2, recruiting macrophages that contribute to KRAS bypass through paracrine S100A4. Our findings elucidate the role of TGFβ signaling in EMT-associated KRAS therapy resistance and identify NFAT5 as a druggable target. Targeting NFAT5 could disrupt this regulatory network, offering a potential avenue for preventing resistance in PDAC.

1 May 2023 in The Journal of Immunology
Verified
Journal Article
Open access
PDF file
QLQiao Lu
Qiao Lu
XCXufeng Chen
Xufeng Chen
HZHua Zhou
Hua Zhou
JLJia Liu
Jia Liu
BNBettina Nadorp
Bettina Nadorp
JWJun Wang
Jun Wang
Although the success of immune-checkpoint blockade has revolutionized cancer treatment, a number of tumors do not respond or develop resistance, including acute myeloid leukemia (AML). A potential mode of resistance is immune evasion of T-cell immunity involving aberrant MHC-I antigen presentation (AP). To map such mechanisms of resistance we identified key AP regulators using specific peptide-MHC-I-guided CRISPR/Cas9 screens in AML. The top-ranked negative regulators were surface protein Sushi Domain Containing 6 (SUSD6), Transmembrane Protein 127 (TMEM127), and the E3 ubiquitin ligase WWP2. SUSD6 is abundantly-expressed in AML and multiple solid cancers, ablation of which profoundly enhanced AP and reduced tumor growth in CD8+ T cell-dependent manner. Mechanistically, SUSD6 forms a molecular complex with TMEM127 and MHC-I, recruiting WWP2 for MHC-I lysosomal degradation. Together with the SUSD6-TMEM127-WWP2 gene signature negatively-correlated with cancer survival, our findings define a membrane-associated AP inhibitory axis as broadly-applicable therapeutic targets for both leukemia and solid cancers. This work is supported by the Mark Foundation ASPIRE Award to J.W. I.A. is supported by the NIH (NCI and NHLBI) (R01CA216421, R01 CA173636, 1R01CA228135, R01CA242020, 1R01HL159175), the Vogelstein Foundation and the Evans MDS Foundation. J.W. is supported by the NIH (R37CA273333-01, R21AI163924-02). Q.L. is supported by the Cancer Research Institute Irvington Postdoctoral Fellowship.